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Psychosocial factors have been shown to be indicative of health recovery in cancer populations.  
However, less is known about Blood and Marrow Transplant (BMT) patients.  This paper 
explores pre-transplant psychosocial factors that may predict poorer health outcomes following 
autologous transplant (AuBMTs) in patients with hematological malignancies.  Participants 
included 130 cancer patients (51.5% male) who completed a pre-AuBMT evaluation (M = 58.39, 
SD = 11.71, range = 21 – 80).   Data extracted include information regarding measures for 
distress (DT), problems in daily life (PPL), depressive symptoms (CES-D) and physical and 
mental health quality of life (PCS-12 and MCS-12).  Health outcomes including cancer-related 
hospital re-admittance, survival rates, and number of medications prescribed within 12 months 
post-transplant were also extracted.   Results indicated that medications were positively 
correlated to PPL score, r(128) = 0.179, p < 0.05, and to CES-D scores, r(128) = 0.220, p < 0.05, 
and inversely related to PCS-12 scores, r(128) = -0.293, p < 0.01.  ANOVA and Welch 
ANOVAs indicated insurance status has a significant effect on mortality rate, depression, and 
physical and health-related quality of life (p<.05).  A stepwise multiple linear regression model 
indicated that approximately 7.9% of the variance of the number of medications used was 
accounted for by PCS-12.  Results suggest that individuals with greater overall problems and 
depressive symptoms and a poorer physical health quality of life (QOL) were prescribed more 
medications.  Additionally, physical health QOL proved to be a significant predictor for 
medication use.  The impact of insurance status on these outcomes is an area for further 
exploration.  This research supports a relationship between psychosocial variables and health 
outcomes for BMT patients with a hematological malignancy and may help inform appropriate 
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Cancer and Blood and Marrow Transplantation  
 The rate of new cancer diagnoses continues to grow at an exponential rate.  Presently, 
cancer remains the second primary cause of death in the United States, leading to nearly one in 
four deaths (American Cancer Society Facts and Figures, 2014).  In 2014, the incidence rate for 
hematological malignancies, cancers which originate in the blood-forming tissues, is expected to 
increase as follows: 24,050 new cases of myeloma, 52,380 new cases of leukemia, and 79,990 
new lymphoma diagnoses (American Cancer Society Facts and Figures, 2014).  The mortality 
rate of these diseases is estimated to be 25 to 48% (Howlader, et al., 2013). Given the increasing 
number of cases and the fairly high mortality rate, medical science is working to establish 
effective treatments that address the disease and also patients’ overall survival and quality of life.  
Often, the most effective treatment option for patients with these diagnoses is bone 
marrow or peripheral blood stem cell transplant (BMT).  There are two primary types of stem 
cell transplant, allogeneic and autologous (Bone Marrow Transplant, 2012).  It is important to 
keep in mind the inherent differences between these two transplant processes, as it may impact 
individuals uniquely. An allogeneic transplant requires having cells or marrow donated from an 
outside source, such as a matched sibling or adult volunteer donor from a national or 
international registry. An autologous transplant involves the treatment, harvest, and storage of 
one’s own stem cells or marrow to be later transplanted back into the body.  As of 2006, there 
were over 15,000 allogeneic and 30,000 autologous transplants completed worldwide (Copelan, 
2006). This number has only continued to increase over time. 
 Following initial treatment and harvest of cells, individuals undergoing an autologous 




body irradiation, which results in a significantly compromised immune system.  Following this 
intensive treatment, one’s own stem cells are then infused into one’s own body in order to 
regenerate normal blood cells.  Following AuBMT, it often takes many months for patients to 
achieve complete immune recovery (Peggs and Mackinnon, 2004; Bone Marrow Transplant, 
2012).  As such, AuBMT is one of the most aggressive, physically intense and demanding 
treatments available for cancer patients (Feigin et al., 2000).   
Following AuBMT, individuals may experience certain complications such as increased 
risk of infection (Bone Marrow Transplant, 2012; as cited in Feigin et al., 2000). Infection often 
occurs within the six weeks after transplant when patients are considered “neutropenic,” which is 
the period of time when white blood cell count is extremely low (American Cancer Society, 
2013). While many of these infections may only be a mild concern for individuals with regular 
immune systems, it is “quite dangerous” for those who have recently received a transplant or 
who are neutropenic.  Engraftment, the period of time when the new bone marrow begins 
producing white blood cells, generally occurs approximately thirty days post-transplant, and 
while it is less likely that a patient will develop an infection following engraftment, it may take 
six to twelve months for a patient’s immune system to fully recover (American Cancer Society, 
2013).   
Bacterial infections are the most common post-transplant complication, but it is also 
likely that a patient may acquire viral or fungal infections (American Cancer Society, 2013), 
which may be “life-threatening” (Bone Marrow Transplantation, 2015).  One study found 
invasive fungal infections as a primary concern for morbidity and infection-related mortality 
among patients receiving BMT (Bhatti, Almyroudis, Segal, 2006).  There are particular 




that have been associated with poor prognosis (Boutati and Anaissie, 1997), and type of 
transplant (allogenic or autologous) did not seem to make a difference in mortality rate (Barnes 
& Marr, 2007 as cited in Nucci et al., 2004).   Not only do infections directly cause increased 
risk to the AuBMT patient, but they also cause indirect harm through increasing risk of extended 
hospital stay or re-hospitalization, and preventing or delaying engraftment or immune recovery 
(Bone Marrow Transplantation, 2015). Therefore, physicians often prescribe antiviral, antifungal 
and antibiotic medications to patients post-transplant in order to both prevent and treat these 
serious infections (Bone Marrow Transplantation, 2015).   
In addition to risk of infection, a patients’ health outcomes may be governed by type of 
diagnosis received prior to the transplant.  Although many hematological malignancies are 
treated with AuBMT, characteristics of specific diagnoses are unique and may guide overall 
treatment outcome as well as interact with a host of other psychosocial factors and health 
variables.   
For the purposes of this paper it is important to differentiate among a few of the specific 
cancer types that fall under the larger umbrella of “hematological malignancies.”  One important 
variation of these forms of cancer is Multiple Myeloma (MM).  MM develops from malignant 
plasma cells.  Healthy and normal plasma cells are particularly important to the immune system 
and can be found in the bone marrow (American Cancer Society, 2014).  However, once these 
healthy cells become cancerous and begin growing more rapidly than normal they can create a 
tumor called plasmacytoma.  Once an individual develops more than one plasmacytoma they are 
diagnosed with multiple myeloma.  Some characteristic features of MM include low blood 
counts, bone and calcium problems, infections, and kidney issues.   MM is not curable, but is 




remissions of several years.  However, the disease will eventually relapse, and patients often 
have to receive regular treatments of chemotherapy, radiation therapy or other drugs to keep the 
cancer in check (American Cancer Society, 2014).   
Another important diagnoses type is lymphomas, which can be broken into the following 
two main categories: Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Lymphoma.  NHL is a 
type of cancer that begins in lymphocytes which are located in the lymph nodes as well as other 
lymphoid tissue (i.e., spleen, bone marrow) and are a crucial part of the immune system.  NHL 
can be even further broken down into specific categories such as B-cell or T-cell lymphomas.  B-
cell lymphomas make up approximately 85% of NHL diagnoses in the United States while T-cell 
lymphomas account for the other 15% (Leukemia & Lymphoma Society, 2013).  There are 
various risk factors for NHL such as, age (i.e., getting older), being male, race (i.e., Asian and 
African Americans), exposure to certain chemicals (i.e., certain herbicides and insecticides, and 
exposure to certain viruses and bacteria such as the Epstein-Barr virus (Leukemia & Lymphoma 
Society, 2013; American Cancer Society, 2014).  In contrast to MM, many times chemotherapy 
treatment will completely cure NHL and mortality rates for this disease have been decreasing 
since the late 1990s (American Cancer Society, 2014).   
The second main category of lymphomas is Hodgkin’s Lymphoma (HL), previously 
known as Hodgkin’s Disease (HD).  The disease name was changed once it was discovered that, 
similarly to NHL, the disease results from an injury to the DNA of a lymphocyte (Leukemia & 
Lymphoma Society, 2013).  Like NHL, HL also develops within lymphocytes, but how this 
lymphoma spreads and responds to treatment is different from NHL, so it is important to 
distinguish between the two.  Physicians can distinguish between the two types through 




Cancer Society, 2014).  Additionally, HL can be differentiated from other types of lymphoma by 
the presence of Reed-Sternberg cells (named for the scientist who first discovered them 
(Leukemia & Lymphoma Society, 2013).  In contrast to NHL, HL is most common in early 
adulthood, predominantly in individuals in their 20s (American Cancer Society, 2014).  Another 
risk factor for HL is previously being infected with the Esptein-Barr virus.   Survival rates have 
increased throughout the past several decades due to improvements in treatment and, currently, 
the 1-year survival rate is 92% and the 5-year rate is 85%.  However, certain factors, such as 
stage of HL or one’s age may alter these rates (American Cancer Society, 2014).  
Finally, the success of a patient’s recovery from a BMT can be uncertain and dependent 
upon multiple psychosocial factors, such as age and overall health, type and dosage of 
chemotherapy or radiation prior to transplant, a range of other complications during and after 
transplant, and genetic makeup (Bone Marrow Transplant, 2012).  It is not uncommon for BMT 
patients to experience lengthy and/or repeated hospital stays, extended periods of social and 
physical isolation due to their immunocompromised nature.  These types of complications 
following AuBMT are not only taxing physically, but socially, emotionally, and financially as 
well (Feigin et al., 2000).   
Biopsychosocial Model of Health 
 When proposing the importance of the biopsychosocial model, Engel (1977) argued that 
a medical model that only understands biological indices does not suffice.  He stated that it is 
imperative to take the patient, the social context in which they live, along with the physician role 
and healthcare system into consideration in an attempt to appropriately understand disease, and 
arrive at rational treatments (Engel, 1977).  The biopsychosocial model is the idea that 




25 years, this model has fueled many new advances in research (Suls & Rothman, 2004).  It 
posits that social, behavioral and psychological dimensions are pertinent to consider, along with 
biological factors, when understanding the framework of physical health and illness.   This 
framework allows researchers and clinicians to develop a multilevel and multisystem approach to 
human functioning (Suls & Rothman, 2004).  In line with a biopsychosocial framework, this 
paper will explore certain psychosocial factors such as distress, depressive symptoms, and 
quality of life to further understand their role in predicting physical health outcomes following an 
AuBMT.   
Distress 
Even without the added stressor of a transplant, cancer diagnoses are often associated 
with significant emotional distress.  It is important to distinguish the variable distress from that 
of depression and quality of life, even though they are all correlated.  Most definitions describe 
distress as “an aversive, negative state” in which an organism is unable to appropriately cope and 
adapt in order to return to psychological homeostasis (as cited by Ward et al., 2008).  More 
specifically, in cancer patients, it may be the case that someone is struggling in coping and 
adapting to a diagnosis or treatment, but is not meeting a clinical depression diagnosis or 
experiencing any significant depressive symptoms (i.e., loss of appetite, low energy, loss of 
interest in activities, suicidal ideation).  In other words, psychological distress may be used as a 
more broad term encompassing stress and both mood and anxiety reactions that do not meet 
clinical criteria.  Furthermore, distress is distinct from quality of life in that one may perceive 
their quality of life to be low, but not be in as great a state of distress as someone who 




varying levels of distress in response to depressive or anxiety-related symptoms and/or changes 
in their differing quality of life facets.    
In cancer patients, the risk of psychiatric distress has been shown to be almost twice that 
of the general population (Hinz et al., 2010), and previous studies have shown that 
approximately one-third of all cancer patients will experience a significant level of distress 
following diagnosis and throughout treatment (see references in Carlson et al., 2004).  While 
emotional distress differs from mood disorders, the two variables may be interconnected.  At 
times, emotional distress can lead to the development of a mood disorder.  Following diagnosis 
and treatment, periods of time that may instill high levels of psychological distress, patients often 
report experiencing various psychological issues such as depressive and anxiety symptoms 
(Kvillemo & Branstrom, 2011).  Previous research has indicated that approximately 25 to 30% of 
cancer patients experience clinically significant distress (Baken and Woolley, 2011).  High levels 
of distress have been shown to impact patients’ quality of life, satisfaction with care and overall 
participation in treatment, as well as recovery -- potentially resulting in a prolonged 
rehabilitation period (Baken and Woolley, 2011; Grassi et al., 2013).  
There are many variables that influence a patient’s level of distress, and, in turn their 
quality of life.  For instance, distress levels have been found to be greater in cancer patients with 
a poorer prognosis, and individuals that have an advanced stage of cancer (Carlson & Bultz, 
2003).  Distress levels have also been found to relate to various demographic factors such as 
female gender, minority ethnicity, lower income, and younger patients.  It is thought that 
younger patients may suffer higher levels of distress due to a greater disruption in social and 
familial roles at an earlier developmental stage (Carlson et al., 2004).  This disruption may 




(Carlson et al., 2004).   Patients have been found to experience distress related to a 
psychological, social or spiritual nature which may interfere with one’s ability to cope with a 
cancer diagnosis (National Comprehensive Cancer Network, 2003).   
Also, certain types of distress may be unique to specific types of cancers and treatments, 
such as BMTs.  For instance, an AuBMT may involve its own potential source of distress for 
hematological cancer patients, as one study found higher levels of emotional distress, in the form 
of anxiety and depression, when compared to those who received an allogeneic transplant 
(Meyers et al., 1994).  Therefore, distress is not only impacted by the cancer disease itself, but 
can be unique to the individual type of treatment, and exacerbated by disruptions in a number of 
other life domains that include one’s own practical concerns, and daily hassles that come along 
with their cancer diagnosis and treatment.   
In addition, distress levels during cancer treatment and recovery may be impacted by 
levels of pre-transplant distress.  Pre-transplant distress may vary depending on multiple factors 
such as prior disease with relapse, treatment history, physical functioning, and psychological, 
financial, and social resources (McGregor et al., 2013).  Pre-transplant distress is an important 
variable to examine when considering factors that contribute to a patient’s recovery trajectory.  
Several studies have indicated that levels of pre-BMT distress predict certain health-related 
outcomes.  McGregor and colleagues (2013) found that increased levels of pre-transplant distress 
among 70 AuBMT patients predicted slower white blood cell (WBC) count recovery following 
transplantation.  This is particularly important, as WBC count is a salient indicator of immune 
function. In another study, Syrjala and colleagues (2004) investigated physical and psychological 




indicated that cancer patients who had slower physical recovery, as measured by more physical 
limitations, also had increased levels of depression prior to BMT (Syrjala et al., 2004).   
Furthermore, pre-transplant distress levels not only impact health outcomes, but 
psychological outcomes as well.  In a study of 125 cancer patients, Broers and colleagues (2000) 
found that patients’ distress throughout the course of their treatment and during the first three 
years following BMT varied depending on whether the patient experienced a low or high level of 
distress pre-transplant.  Other studies have shown that pre-transplant emotional distress was 
correlated with distress at three and twelve months post-transplant (Fife et al., 2000), and that 
pre-BMT distress levels had a predictive value accounting for 81% of post-transplantation 
distress (Lee et al., 2005).    Therefore, these findings suggest that higher levels of pre-transplant 
distress may be a risk factor for experiencing increased psychological symptoms even following 
an AuBMT. 
While greater distress has been found to predict poorer health and recovery, other 
research has found that decreased levels of distress may predict better mental and physical health 
outcomes.  Some evidence suggests certain forms of coping may be helpful for handling distress.  
Rodrigue and colleagues (1999) examined psychological variables in 92 patients prior to their 
BMT and found that increased levels of affective functioning and social support pre-transplant 
significantly predicted increased quality of life and survival status.  In addition to distress, other 
psychosocial factors, such as age, relationship support, education, mood, and adjustment have 
been related to a variety of health outcomes, including survival rates, in the BMT population 
(Hoodin, Kalbfleisch, Thornton, & Ratanatharathorn, 2004).  These findings underscore the need 
for screening and psychological interventions to be employed pre-transplant so that that patients 




As demonstrated above, research has shown that pre-transplant distress is an important 
variable to consider in overall treatment and recovery prognosis for cancer patients undergoing 
BMTs.  However, studies specifically investigating pre-transplant distress in AuBMT patients 
are lacking.  
Depression 
In addition to examining pre-transplant distress levels, it is also meaningful to consider 
other psychological variables such as depressive symptoms.  Depressive symptoms such as 
impaired sleep, increased or decreased appetite, and lower energy can have a negative impact on 
one’s overall health.  Furthermore, depressive symptoms have been shown to be linked with 
more severe concerns such as decreased immune system functioning and mortality (see 
references in Miller, 1998).  Within the general population, the association between depressive 
symptoms and mortality has been well documented (see references in Loberiza et al., 2002).  
Robust meta-analyses provide strong evidence for this relationship.  Harris and Barroclough 
(1998) conducted a meta-analysis with 19,000 individuals in which they found that, when 
compared to the general population, people with depression had increased mortality rates from 
infectious, respiratory, nervous system and circulatory disorders.  These harmful effects on one’s 
health may differ depending on the particular population. 
While depressive symptoms can be troublesome for individuals in the general population, 
they can be particularly problematic for those within a cancer population due to the associated 
health risks, including higher mortality.  Evidence suggests a co-occurrence between cancer and 
depression with bidirectional relationships that may link depression with cancer progression (see 
references in Giese-Davis et al., 2011).  Depression in cancer patients has been associated with 




poorer treatment adherence, greater risk of cancer relapse, and decreased health-related quality of 
life (Reich, 2008).   
The prevalence rate of depression tends to vary by cancer site (Onitilo et al., 2006).  
Increased rates have been found in patients experiencing greater physical disability, advanced 
illness, and significant pain (Sellick & Crooks, 1999). For example, in a meta-analysis of studies 
assessing for mood and adjustment disorders in cancer patients using psychiatric diagnostic 
interviews, prevalence rates for depressive disorders were estimated at 24.6% among patients 
treated in palliative-care settings and 20.7% in patients treated in oncology and hematology 
settings (Mitchell, Chan, Bhatti, Halton, Grassi, Johansen, & Meader, 2011).  In a related meta-
analysis, researchers examined eight community-based sample studies and 15 studies within 
cancer patients, and found that depression was related to greater rates of mortality (Chida et al., 
2008).  Additionally, Satin and colleagues (2009) found that depression predicted higher 
mortality in cancer patients in their meta-analysis of 25 individual studies.    Furthermore, 
Pinquart and Duberstein (2010) conducted a meta-analysis in which they evaluated results from 
76 prospective studies of cancer patients with various diagnoses.  Their results indicated that, 
depression defined either categorically or dimensionally, was associated with elevated risk for 
mortality in cancer patients.   
It is particularly noteworthy to mention that depression seems to have a more negative 
impact on mortality in individuals with cancer when compared to those without.  Onitilo and 
colleagues (2006) analyzed data on 10,025 individuals, and created four groups based on cancer 
and depression status including (a) no cancer, no depression, (b) depression, but no cancer, (c) 
cancer, but no depression, and (d) cancer and depression.  Researchers looked at outcome data 




of death from all causes, even if not related with depression or cancer.  Furthermore, they found 
variability within the “cancer and depression” group, in that the relationship between depression 
and increased risk of death varies depending on cancer site.  Researchers found a 0.47 increased 
risk of death for patients with gastrointestinal cancer, 0.39 for those with lung cancer, 0.07 for 
patients with skin cancer and 1.13 in patients with other cancers (Onitilo et al., 2006).  In this 
study, patients with hematological cancers were not evaluated individually, but were grouped 
along with additional cancer diagnoses in the “other” category. 
While an examination of research on depressive symptoms within the general cancer 
population is useful, more literature focusing specifically on pre-transplant depressive symptoms 
in the hematological malignancy and BMT population is warranted. Overall, there seems to be a 
paucity of research examining depressive symptoms specifically within this group, and 
particularly among patients who received AuBMT.  However, there have been a few studies that 
indicate the importance of studying depression among patients within BMT populations, as 
depressive symptoms have been shown to be predictive of post-transplant outcomes.  For 
instance, study results included within a recent meta-analysis have shown that depression 
predicted shorter survival time in leukemia and lymphoma patients (Pinquart & Duberstein, 
2010).  In addition, pre-transplant levels of depression have been associated with higher 
mortality during the period between 6 and 12 months following BMT.  Also, levels of depressive 
symptoms pre-BMT predicted vulnerability to continued difficulties with depression after BMT 
(Massie, 2004; Artherholt, Hong, Berry, & Fann, 2014).  Given the unique constellation of 
symptoms and specific difficulties within each cancer diagnosis, it is important not to assume 
that depressive symptoms function similarly in all patients with cancer, or across all cancer 




who undergo AuBMT would only help further elucidate how depressive symptoms impact these 
specific patients’ health outcomes within the context of this specific treatment. 
It may be helpful to clarify that while depression and distress may seem similar, they 
have important conceptual differences.  For example, the broad variable of distress may 
encompass many other variables such as general stress, spiritual concerns, family problems, or 
practical issues.  In the specific case of a BMT patient, distress may be based on the individual’s 
fear or concern associated with their cancer diagnosis or transplant as it impacts various aspects 
of life.  However, depressive symptoms are usually conceptualized as criteria of a clinical major 
depressive episode (i.e., lack of interest in activities, low energy, poor appetite, feeling “down” 
or “depressed”).  One could say, patients who are depressed are typically distressed, but not all 
patients who are distress are depressed. Therefore, assessing the impact of both of these variables 
may provide clinicians and researchers with valuable and unique information. 
Quality of Life 
When an individual is experiencing significant levels of distress and/or depressive 
symptoms, it may be likely that these symptoms are also impacting their overall quality of life 
(Vitek, Rosenzweig, Stollings, 2007).  In the past couple of decades, medicine has transformed 
from understanding suffering through focusing solely on the physical manifestations of a disease 
to also including the psychosocial impact (Armstrong, Lilford, Ogden, and Wessely, 2007).  The 
assessment of quality of life has allowed clinicians and health psychologists to assess both 
immediate clinical symptoms as well as distal consequences (Armstrong et al., 2007).  These 
distal consequences, assessed through quality of life measures, are comprised of both physical 
and mental factors.  For instance, physical factors may include quality of physical functioning, 




can impact quality of mental health may be one’s level of vitality, social functioning, and role 
limitations due to emotional or physical problems (Ware, Kosinski, & Keller, 1996).  This 
measurement of quality of life that has emerged over the past few decades has been instrumental 
in health psychology as it has given clinical symptoms a new and deeper meaning and 
transformed the patient self-report into the central component of defining health and illness 
among multiple populations (Armstrong et al., 2007).   
Within the general cancer population, quality of life assessment has flourished during the 
past couple of decades due to improved cancer treatment and survival rates (Ferrell & Grant, 
1995).  Studies have shown that assessing quality of life in cancer patients can lead to improved 
treatment and may even be as prognostic as certain medical factors (Montazeri, 2008).  Research 
in quality of life among cancer patients has also been shown to highlight particular directions 
needed for more efficient and effective treatment.  Assessment within a cancer population 
requires researchers and clinicians to measure unique facets that may not be as critical in the 
general medical population, such as measuring quality of life for patients in different stages of 
cancer progression, and among patients in various stages of treatment (i.e., pre-treatment, active 
stage, post-treatment).  Furthermore, various types of cancer and cancer treatments have been 
studied such as prostate, colon, and lung cancer, with the most research having been done within 
breast cancer patients (Montazeri, 2008).  It is important to consider all of these distinctive 
variables when assessing quality of life in cancer patients in order to gain the most thorough 
understanding of each particular population and subgroup. 
  Specifically, it is important to further understand quality of life factors in the BMT 
population given the unique impact of this treatment regimen on cancer patients.  There have 




such as fatigue, sexuality concerns, and family distress created by the illness have been reported 
(Whedon & Millis, 1995).  To gain a better understanding of impairments in quality of life 
specific to a BMT population, some research has examined and compared quality of life in BMT 
survivors to “healthy” individuals.  Hann and colleagues (1997) found that, in comparison to a 
“healthy” population, BMT patients experienced impairments in physical role functioning, 
general health, vitality, social functioning, and emotional role functioning.  Furthermore, this 
decreased quality of life was associated with a prolonged hospital stay, lower income, and 
greater symptom prevalence, severity and distress (Hann et al., 1997).   
Other studies have investigated the impact of pre-transplant quality of life on post-
transplant outcomes, particularly on survival rates.  For example, Andorsky and colleagues 
(2006) conducted a longitudinal study in which they collected self-reported quality of life data 
from cancer patients prior to their BMT, and again at six and 12-month follow-up.  The quality 
of life measure consisted of information about patients’ mental and physical health functioning. 
Results indicated that pre-transplant quality of life data were a strong predictor for post-
transplantation self-reported recovery at six months. Furthermore, although the variable disease 
risk is normally highly predictive of survival; in this study, quality of life scores proved to be 
more predictive of this benchmark variable.   
It is clear that the assessment of quality of life has become an increasingly important 
aspect in health psychology and oncology research in general.  While there have been some 
studies conducted within a BMT population, few studies have examined the quality of life 
specifically in individuals with a hematological malignancy who undergo an AuBMT. Given the 




this particular population to better understand the significance of this variable within AuBMT 
patients. 
Financial Burden 
Not only is it important to understand how a patient’s distress, depressive symptoms and 
quality of life influence recovery, but also how this recovery process influences other critical 
factors such as medical costs.  Due to a patient’s poorer recovery following treatment, patients, 
healthcare providers, and the health system as a whole may experience increased financial strain.   
In recent years, cancer treatment costs have increased drastically and created financial burdens 
for both patients and third-party payers (see references Greenberg, Earle, Fang, Elder-Lassai & 
Neumann, 2010).   
Cancer patients have been shown to have an increased risk of declaring bankruptcy when 
compared to the general population.  Ramsey and colleagues (2013) conducted a study in which 
they examined the finances of individuals, twenty-one years and older diagnosed with cancer 
between 1999 and 2009.  Cases were identified using the National Cancer Institute’s 
Surveillance Epidemiology and End Results (SEER) program and compared to control group 
data obtained from the LexisNexis data repository, the largest commercial repository for public 
data in the United States.  Their findings suggest that cancer patients were 2.65 times more likely 
to declare bankruptcy than people without cancer.   
With increasing rates of cancer diagnoses, total cancer costs are growing, along with the 
costs for specific treatment options such as BMT.  As of 2009, the total cost of cancer was 
estimated to be $216.6 billion; direct medical costs (total of all health expenditure) to be 86.6 
billion, and indirect mortality costs, which is the cost of lost productivity due to premature death, 




expected to increase in 2014, these total costs are likely to continue to grow.  For individuals 
receiving AuBMT, the cost of the transplant is tremendous, totaling approximately $360,000 
(National Foundation for Transplants, 2010).  While insurance may cover some costs for 
patients, depending on their coverage, BMT patients will still incur a number of other costs, such 
as lodging for follow-up care, prescriptions, potential childcare, and over-the-counter related 
medication and medical supply costs.  This also fails to capture the loss of productivity and 
possibly employment that patients face over the long course of illness, treatment, and recovery 
from AuBMT.  
Expenses for patients vary depending on medical and treatment issues specific to one’s 
cancer diagnosis and associated end of life (EOL) costs.  Chastek and colleagues (2012) 
investigated the costs of health care services incurred by patients and health care providers 
through examining medical and pharmacy claims and enrollment information from the Life 
Sciences Research Database.  Medical claims came from industry-standard forms as well as 
electronic forms submitted for pharmacy claims.  Researchers retrospectively studied end of life 
(EOL) costs at both six months and one month prior to death, and examined multiple medical 
outcomes including office visits, ER visits, and outpatient services.  These services were deemed 
cancer-related if a cancer diagnosis appeared in the primary or secondary position of the claim.  
They evaluated a total of 28,530 patients with cancer who had a medical claim between 2002 and 
2009; 9% of those patients had a hematological malignancy.  Overall, results indicated that 
hematological cancer patients had a greater mean EOL cancer-related costs ($160,361) compared 
with patients with a solid tumor ($59,822).  Additionally, acute cancer-related inpatient stays 
were also higher for patients with a hematological malignancy than a solid tumor ($121,651 v 




$4,040, and for hospital outpatient procedures it was $10,123.  Meanwhile, the lymphoma 
patients, one type of hematological malignancy, had a unanimously higher mean cost for these 
three variables.  The mean costs of 1,459 lymphoma patients were as follows: $651 for 
emergency room visit, $4,095 for office visits, and $16, 565 for hospital outpatient procedures 
(Chastek et al., 2012).  
These higher EOL expenses for hematological cancer patients and their healthcare 
providers indicate an increased need to understand ways in which to lower post-transplant 
medical costs.  If pre-transplant distress, quality of life and depressive symptoms are associated 
with recovery and health outcomes, implementing effective psychological screening and 
interventions prior to transplant may also relieve financial strain that may be associated with 
poorer recovery. 
Insurance Status 
The aforementioned cancer treatment costs bring to mind the role of health insurance.  
The impact of these astronomical costs on one’s overall wellbeing is even more salient when the 
role of insurance status is considered.  Previous studies have shown that the insurance status of 
cancer patients may predict health outcomes (i.e., Rodriguez, Ward, Perez-Stable, 2005; Halpern, 
Bian, Ward, Schrag, Chen, 2007) even after adjusting for race, age, sex, and zip code estimated 
income (Chen, Schrag, Halpern, & Ward, 2007; Chen, Schrag, Halpern, Stewart & Ward, 2007; 
Cokkinides, Bandi, Siegel, Ward, & Thun, 2007; Halpern et al., 2008; Ward et al., 2008 as cited 
in Kwok et al., 2010).  Other studies have shown that individuals who are underinsured or 
insured by Medicaid are more likely to experience more advanced stages of cancer (Chen et al., 
2007).  Kwok’s study (2010) found that patients with Medicaid or who were uninsured were at 




insurance, after adjustment of a number of demographic factors including treatment, cancer stage 
and socioeconomic status (SES).  These studies suggest that insurance status may be one of the 
most prominent demographic factors that interacts with a patient’s overall health outcomes, and 
should be considered along with examining other psychosocial variables.   
Need for Psychosocial Screening and Intervention 
Due to medical advancements, BMT survival rates have improved considerably in the 
past few decades (Horowitz, 1999).  Therefore, with increased survivors, further understanding 
the course of BMT recovery along with potential risk factors for poorer health outcomes is 
warranted (Syrjala et al., 2004).  Although there is a strong association between the 
aforementioned pre-transplant variables and post-transplant psychological and medical 
outcomes, only 33% of patients with cancer who experience comorbid distress are recognized 
within an oncology setting, and referred to an appropriate intervention (Grassi et al., 2013).   
However, the oncology community has begun to appreciate that it is not only important 
to try to extend the length of, but also to try to increase the quality of a patients’ life which can 
be done through proper psychosocial care (Jacobsen & Wagner, 2012).  This is due to an 
increased recognition that psychosocial care is important in the comprehensive treatment of 
cancer patients and should be integrated into their routine treatment plan (Jacobsen & Wagner, 
2012).  Recently, the American College of Surgeons (ACoS) Commission on Cancer (CoC) has 
implemented a new patient-centered accreditation that requires programs to conduct 
psychosocial distress screening and referral for psychosocial care (Wagner, Spiegel & Pearman, 
2013).   
In order for the recently mandated distress screening to be most helpful, there is an 




variables, as well as greater awareness of the predictive significance of these variables upon 
admission to the hospital or initiation of treatment.  If these variables are more readily identified 
in individuals undergoing AuBMT, is it possible that more of these patients in need of 
psychological intervention may then be identified?  Furthermore, would identifying these 
variables also improve their health and psychological outcomes, as well as reduce their overall 
costs of transplant-related health incidences (i.e., infection, re-admission)? 
Currently, there are no conclusive answers to these questions.  While there have been 
multiple studies investigating associations among psychosocial and physical health factors in 
cancer patients, little research has been done specifically in BMT patients prior to their 
transplant, and even less research has been conducted on the even more specialized AuBMT 
population.  It is important to remember that individuals with certain cancer diagnoses may have 
unique psychological symptoms separate from other cancer types (Lengacher et al., 2012), and 
that those with hematological cancer may differ in these levels pre-transplant.  Additionally, 
individuals with various cancer diagnoses may respond differently to various psychological 
assessments.  For example, research has indicated a differential response on psychological 
measures that assess patients with hematological disorders and those with other cancer types, 
such as breast cancer (Ahles, Tope, Furstenberg, Hann & Mills, 1996).   
More specifically, there are noteworthy differences that distinguish an autologous from 
an allogeneic BMT, such as the auto-harvest of one’s own bone marrow or stem cells, and the 
absence of graft versus host disease risk (Grassi et al., 1996).  There also may be differences in 
treatment-related side effects and mortality between allogeneic and AuBMT patients.  For 
example, one study found that there is a consistent pattern of relapse often seen with prolonged 




to an allogeneic BMT, in patients with certain types of lymphoma (Verdonck, Dekker, Lokhorst, 
Petersen, Nieuwenhuis, 1997).  These inherent characteristics of AuBMT, and the diseases 
treated, may uniquely impact the interaction and relationship between pre-transplant 
psychological functioning and post-transplant health recovery.  Further understanding how pre-
transplant psychosocial concerns impact physical health outcomes of hematological cancer 
patients, post-AuBMT, may help in identifying “high-risk” patients in this specific population.  
With better identification of these concerns, it may be possible to better allocate resources, 
implement psychological intervention, reduce medical costs, and enhance overall recovery and 
health. 
Aim & Hypotheses 
While a significant amount of research has been conducted in the general cancer 
population regarding psychological symptoms and health outcomes, less is known about BMT 
patients, and even less about differences between different types of transplant such as allogeneic 
versus autologous BMT.  BMT patients are different from other cancer populations in that they 
face more lifestyle-limitations with treatment, greater mortality and higher healthcare costs 
(Chastek et al., 2012).  It is important for researchers and clinicians to understand the 
psychological aspects of care from a whole-person framework in this specialized, high-risk and 
growing population.  Furthermore, in order to better understand these aspects of care, it is critical 
to differentiate between the two specific categories of BMT, allogeneic and autologous, as each 
type is associated with its own challenges in recovery as well as physical and psychological 
functioning.  Therefore, this study will specifically aim to investigate the psychological aspects 




The overall aim of this study is to highlight pre-transplant psychological factors that may 
predict poorer health outcomes following AuBMT.  Increasing knowledge about these pre-
transplant psychological variables may be clinically relevant in developing effective 
psychosocial screenings and interventions for BMT patients.  No other study, to date, has 
examined the effect of pre-transplant distress, depressive symptoms and quality of life on health 
outcomes in patients with hematological cancers post-AuBMT.   
The present study plans to test the following three hypotheses:  
(1) Greater levels of distress, depressive symptoms, and poorer self-reported quality of 
life (physical health-related quality of life; mental health-related quality of life) will 
predict greater number of medications (antiviral, antifungal, and antibiotic) used up to 
twelve months following transplant. 
(2) Greater levels of distress, depressive symptoms, and poorer self-reported quality of 
life (physical health-related quality of life; mental health-related quality of life) will 
predict a greater number of re-hospitalizations up to twelve months post-transplant.  
(3) Greater levels of distress, depressive symptoms, and poorer self-reported quality of 
life (physical health-related quality of life; mental health-related quality of life) will 
predict mortality up to twelve months after AuBMT. 
Methods 
Participants 
A previous study conducted a retrospective chart review for 254 consecutive patients who 
completed evaluations at the University of Kansas Cancer Center for bone marrow or peripheral 
blood stem cell transplant (BMT) between January 2012 and December 2013.  Data extracted 




treatment history.  Results of three psychosocial measures routinely administered as part of the 
clinical pre-transplant assessment for the patients’ preparation for BMT were also extracted. No 
identifying information was collected and patients were not separately consented for inclusion in 
this retrospective study.  Patients for the current study were limited to AuBMT patients. Thus, 
patients were excluded from the original sample of 254 if they were being evaluated for an 
allogeneic transplant (unrelated donor or matched sibling), or alternative donor transplant (i.e., 
cord blood or haploidentical donor).  The current study and retrospective chart review were both 
approved by the University of Kansas Medical Center (KUMC) IRB.   
Of the 254 cases previously screened for eligibility, 137 met the aforementioned study 
inclusion criteria.  Out of the 137 potential participants, seven were excluded for the following 
reasons: transplant delayed for personal or medical reason (n = 3), medical information not 
included in KU Cancer Center database (n = 3), transplant date did not allow for medical 
outcome data collection past six months at this time of data extraction (n = 1).  See Figure A.   
The final sample included 130 KU Cancer Center patients (51.5% male), over the age of 
18 at the time of pre-transplant evaluation (M = 58.39, SD = 11.71, range = 21 – 80).  Due to this 
study being conducted as retrospective chart review, data on race/ethnicity was unavailable.  All 
were evaluated for an AuBMT, and completed all clinical assessment measures. All participants 
had been diagnosed with one or more hematological condition(s) or malignancies including the 
following:  Multiple Myeloma (n = 86; 66.2%), Non-Hodgkin’s Lymphomas (n = 32; 24.6%), 
Hodgkin’s Lymphoma (n = 11; 8.5%), and Plasma Cell Leukemia (n = 1; < 1%).   
Insurance status was also assessed as a demographic variable, as previous studies have 
shown that the insurance status of cancer patients may predict health outcomes (i.e.,  Rodriguez, 




insurance type, the various types of insurance listed on each patient’s electronic medical file 
were recorded. This included the following: self-pay, Medicare, Blue Cross Blue Shield, 
commercial, Tricare, and Medicaid.  After consulting with an oncology nurse clinician who was 
knowledgeable about insurance-related patient issues, the following three insurance categories 
were developed: commercial (n = 49), Medicare (n = 56) and underinsured (n = 25).  The 
commercial group included patients with Blue Cross Blue Shield and Tricare insurance.  The 
underinsured group included patients who “self-paid”  or relied on Medicaid.  The participants’ 
insurance status is as follows: Medicare (n = 56; 43.1%), commercial (n = 49; 37.7%), and 
underinsured (n = 25; 19.2%). 
Measures 
 Demographic and clinical information. Participants’ gender, age, diagnosis, and 
treatment history were gathered through the pre-transplant evaluation and/or review of each 
patient’s medical chart. 
Distress Thermometer (DT) and Patient Problem List.  The DT (National 
Comprehensive Cancer Network, 2003; Roth et al., 1998) was used to measure the subjective 
level of a patient’s psychological distress.  This measure is a single, Likert-scale item in which 
the patient is asked to indicate how much distress they have experienced in the past 7 days.  The 
thermometer is based on a scale from 0 (No distress) to 10 (Extreme distress).  The DT has been 
validated in a sample of patients anticipating BMT by comparing its scores with scores on the 
Center for Epidemiologic Studies Depression Scale (CES-D; Ransom, Jacobsen, & Booth‐Jones, 
2006).  A score of four and above has been found to differentiate between individuals who are 
experiencing clinically significant distress and those who are not.  The specificity and sensitivity 




a significant need for further evaluation (Jacobsen et al., 2005).  Additionally, a higher score on 
the DT has been associated with increased anxiety and depression, and worse performance status 
(Ransom et al., 2006).   
The Patient Problem List (National Comprehensive Cancer Network, 2003) is a self-
reported checklist of 33 common concerns of cancer patients which typically accompanies the 
DT on a single sheet.  Patients are asked to indicate whether or not each of the problems has 
bothered them in the past seven days (i.e., “yes”, “no”).  Questions on the checklist assess each 
of the following domains: Family Problems, Practical Problems, Emotional Problems, 
Spiritual/Religious Concerns, and Physical Problems.  These domains have been identified in 
other papers following established procedure in the field (Jacobsen et al., 2005; Hollingworth et 
al., 2013; NCCN, 2015). The PPL was created to identify areas in which further evaluation and 
psychosocial service were needed when the DT cutoff score is four or greater (NCCN, 2003; 
Jacobsen et al., 2005). One study looked at cumulative problems endorsed across all domains, 
and found individuals who had increased distress endorsed significantly more PPL items in 
general (Shim, Shin, Jeon, Hahm, 2008). For this study, the total score of these domains 
combined were considered as a representation of overall psychosocial difficulties, and this single 
score was looked at separately from the overall single-item distress thermometer score.   
Center for Epidemiologic Studies Depression Scale (CES-D).  This widely-used 
instrument (Radloff, 1977) is intended to measure symptoms of depression.  The CES-D is a 20-
item, 4-point Likert scale that ranges from 0 (Rarely or none of the time) to 3 (Most or all of the 
time) which assesses mostly somatic or emotional symptoms of depression.  The psychometric 




been established as a cutoff point to identify participants who are experiencing clinical levels of 
depressive symptoms (Myers & Weissman, 1980; Radloff, 1977).  
 Medical Outcomes Study 12-Item Short-Form Health Survey (SF-12).  The SF-12 
(Ware et al., 1996) is a 12-item, self-report tool which is a well-validated measure used to 
evaluate health-related quality of life.  The items measure a participant’s functioning in the 
following eight domains: physical functioning, role-physical (i.e., role limitations due to physical 
problems), bodily pain, general health, vitality, social functioning, role-emotional (i.e., role 
limitations due to emotional problems), and mental health.  Two quality of life scores were 
determined from these eight domains.  The physical health composite scale (PCS-12) is a sum of 
the initial four domains while the mental health composite scale (MCS-12) is comprised of the 
last four domain scores.  Summary scores are transformed so that the mean population scores are 
50 and the standard deviations are 10, with the range of possible scores being 0 to 100. Higher 
scores indicate more adaptive functioning and quality of life within the two scales.  
Procedure 
 Participants completed study measures, as aforementioned, as part of the standard clinical 
evaluation in preparation for BMT.  A retrospective medical chart review was then conducted to 
extract the following medical outcomes data for patients’ post-AuBMT:  
1) Rate of re-admittance to the hospital in a twelve-month period. 
2) Number of antiviral, antifungal, and antibiotic medications used. 
3) Mortality rate twelve months post-transplant. 
Hospital re-admittance was determined based on number of overnight, re-admissions to 
the hospital following transplant.  Re-admissions or E.R. visits that did not include an overnight 




evaluated both continuously and categorically.  The binary outcome variable of hospitalization 
was defined as “0” (no re-hospitalization) or “1” (any re-hospitalization).   
The only types of medications considered in these analyses were antifungal, antibiotic, or 
antiviral medications.  This is because these are the types of medications prescribed by 
physicians in order to prevent or treat an infection within this population.  For analyses, these 
three types of medications were tallied over the course of 12 months post-transplant, and 
summed as one “medication” variable.  In order to accurately account for the antiviral, 
antifungal, and antibiotic medications needed following the AuBMT, no medications that were 
used during the actual transplant process were considered in analyses.  For example, if a patient 
were hospitalized while undergoing their AuBMT, none of the medications prescribed during 
that initial hospital stay were included.  Additionally, inpatient and outpatient medication 
dosages were tallied differently.  If a patient was hospitalized as an inpatient for multiple days, 
and they received multiple IV doses of a certain antiviral, antifungal, or antibiotic medication, 
each IV dose prescribed was considered a separate dose of medication, and counted as “one” in 
the analyses.  However, if patient was prescribed an antiviral, antibiotic, or antifungal medication 
on an outpatient basis, then only one medication dose was counted for that particular prescription 
bottle for the patient, and tallied as “one” in the analyses.  This procedure for tallying 
medications was consistent across all patients.  Medications were calculated in this way in order 
to best capture greater variability among patients, account for the level of severity of infection, 
account for the increased concentration in each inpatient IV dose of a particular medication, and 
maintain consistency across patients in analyses.   
Data on mortality were obtained through the use of the KU Cancer Center  electronic 




to confirm whether or not date of death occurred within 12 months post-transplant.  For this 
study’s purpose, patient was not coded as “deceased” if patient passed away after 12 months 
post-transplant. 
Medical Consultation 
In order to calculate the number of medications, the list of medications for each patient 
was retrieved from the KU Cancer Center electronic medical files.  Once each file was attained, 
medical professionals at the KU Cancer Center helped to confirm particular cancer-specific 
antifungal, antibiotic and antiviral medications prescriptions, on each patients’ list, issued within 
twelve months of the initial transplant procedure. 
Statistical Analyses 
Data analyses were conducted using IBM SPSS version 22.  Two-tailed tests of 
significance were conducted with the level of significance set at p < 0.05 for all analyses.  
Descriptive and frequency statistics were examined for the following variables: age, 
gender, diagnosis code, and insurance type.  These statistics were also examined for the three 
health outcome variables: total medications, number of hospitalizations, and mortality.  
Furthermore, means were observed for the following predictor variables: Distress score, Total 
Problems score, CES-D score, and SF-12 (PCS-12 and MCS-12) scores.  All descriptive 
statistics are reported in Tables 1 through 4.   
Main analyses consisted of separate stepwise linear regression models and/or logistic 
regression models to examine whether any of the five following continuous, independent 
variables (DT score, patient problem list score, CES-D score and PCS-12 and MCS-12 scores) 
were significant predictors of the health outcome variables (medications used, hospital 




regression model using a backward elimination procedure, was used to capture the continuous 
nature of the variables medications and hospitalizations.  All predictors were initially included in 
the model, and then, through the use of the backward elimination process, predictors that did not 
account significantly for the outcome variable were discarded (reference Hocking, 1976 for 
further discussion of this method).   
Binary logistic regression was used for mortality as well as hospitalizations as this type of 
regression can be helpful for modeling the independence of a binary response on an explanatory 
variable which may be categorical or continuous (Bewick, Cheek, Ball, 2005).  Due to the low 
number of re-hospitalizations per patient (M = 0.55; SD = 0.81; Range = 0-4), both linear and 
logistic regression analyses were used to accurately assess hospitalization data.  
Bivariate correlations between the following variables were computed to assess for 
significant relationships: gender, age, DT score, PPL score, CES-D score, PCS-12, MCS-12, 
medications, hospitalizations, and mortality.  Due to the exploratory nature of analyses, the 
bivariate correlations were helpful to determine potentially important relationships and trends 
among variables that may help inform future research. See Table 6. 
Finally, relevant demographic data such as diagnosis and insurance status were assessed 
to identify if either of these factors independently predicted poorer health outcomes among 
patients.  The Levene’s test was used to test for the assumption of homogeneity of variance of 
the data (Levene, 1960; Glass, 1966).  Depending upon the outcome, either a standard one way 
analysis of variance (ANOVAs), for homoscedastic data, or Welch’s ANOVA (Welch, 1947; 
Welch, 1951), for heteroscedastic data, was conducted in order to compare the differences in 
means among diagnosis code and insurance for each of the following variables: medications, 




variance heterogeneity, the Welch procedure provides superior control of Type I errors and better 
power compared to the standard ANOVA (Tomarken & Serlin, 1986). Following significant F-
tests, post hoc comparisons were conducted.  In cases where data were homoscedastic, Tukey’s 
HSD was used (Tukey, 1949).  Games-Howell was used for data that were heteroscedastic 
(Games & Howell, 1976).   
Results 
Preliminary Analyses 
Covariates.  Preliminary analyses were conducted to identify covariates. 
Influence of diagnosis. Either a one-way ANOVA or Welch’s ANOVA, depending on 
each variables’ homogeneity of variance, were conducted to compare the effect of diagnosis on 
the following variables: DT, PPL, CES-D, PCS-12, MCS-12 scores and hospitalizations, 
medications, and mortality for the diagnoses of MM, NHL and HL.  Analyses excluded the PCL 
group due to the very low subsample size (n = 1).  No significant differences were found.  Means 
and standard deviations are provided in Table 3.  
Influence of insurance status.  A series of one-way between subjects ANOVAs and 
Welch’s ANOVA tests were conducted to compare the effect of insurance status on the 
following variables: DT, PPL, CES-D, PCS-12, MCS-12 scores and hospitalizations, 
medications, and mortality for commercial, Medicare and underinsured groups.  Although 
mortality rate did not meet the assumption for homogeneity of variance, ANOVA was used in 
this case as one group had a variance of zero, resulting in the Welch’s test being invalid.  There 
was a significant effect of insurance status on mortality, F(2, 127) = 6.206, p = 0.00, and 
depression scores on the CES-D, F(2, 59.651) = 3.281, p = 0.044.  Games-Howell post hoc tests 




depression score (p=.076) when compared to the commercial insurance group; the Medicare 
group was not significantly different from the other two insurance groups on either variable.  A 
Welch’s ANOVA indicated a significant effect of insurance status on mental health-related 
quality of life scores on the MCS-12 F(2, 56.283) = 4.598, p = 0.014 in which a Games-Howell 
test indicated significantly poorer mental health quality of life among the Medicare group when 
compared to the commercial group (p<.05); the underinsured group was not significantly 
different from the other groups.  Insurance status significantly impacted scores on the PCS-12, 
F(2, 127) = 3.206, p = 0.044, in which a Tukey’s HSD post hoc test revealed the underinsured 
group had marginally poorer physical health quality of life when compared to the commercial 
group (p=.058) and the Medicare group (p=.056). These data can be found in Table 4 and Table 
5.  
Influence of age and gender. Bivariate correlations were examined for the remainder of 
the study variables. As shown in Table 6, gender had a significant relationship with several of the 
predictors, specifically, being female was associated with DT scores, r(128) = -0.226, p < 0.01 
and being male was positively correlated with MCS-12 score, r(128) = 0.213, p < 0.05. There 
were no differences based on age.   
Psychosocial self-report scales. Bivariate correlations indicate a high level of 
multicollinearity among psychosocial variables.  As shown in Table 6, the DT, PPL, CES-D, 
PCS-12 and MCS-12 are all significantly correlated.  
Health outcomes. The health outcome variables of medications, hospitalization, and 
mortality correlated in the expected direction.   For example, medications positively correlated 




.01.  Also, hospitalizations was positively correlated with mortality, r(128) = 0.343, p < 0.001.  
See Table 6. 
Hypothesis One: Medications 
Hypothesis one tested whether the self-reported psychosocial variables (DT, PPL score, 
CES-D score, PCS-12 and/or MCS-12) predicted medication use in the 12 months following 
AuBMT.  To better understand specific relationships, bivariate correlations among medications 
and the psychosocial variables were examined.  Medications were found to be positively 
correlated to PPL score, r(128) = 0.179, p < 0.05, and also to CES-D scores, r(128) = 0.220, p < 
0.05.  These results suggest that individuals who self-reported greater problems and depressive 
symptoms were prescribed more medications during the 12 months post-transplant. Also, higher 
PCS-12 scores were inversely related to number of medications used, r(128) = -0.293, p < 0.01.  
Therefore, patients who reported better physical health quality of life were prescribed fewer 
medications during 12 months post AuBMT.  All correlations are reported in Table 6.   
Due to high collinearity among psychosocial variables, a stepwise multiple linear 
regression model was conducted to identify a unique source of variance that predicted 
medication use. At step 1 of the analysis, PCS-12 entered into the regression equation as 
significantly related to medications F(1, 128) = 12.05, p < 0.01.  The adjusted R
2
 was 0.079, 
indicating that approximately 7.9% of the variance of the number of medications used was 
accounted for by PCS-12, physical health-related quality of life.  Distress (t = 0.44, p > 0.05), 
PPL (t = 0.78, p > 0.05), CES-D (t = 1.50, p > 0.05), and MCS-12 (t = -0.80, p > 0.05), scores 
were removed from the equation during the following steps of the analysis.  Thus, PCS-12 was 




Additionally, in order to control for covariates, a second model was completed which 
included age, diagnosis, insurance status and gender into the model. The inclusion of these 
potential covariates in the stepwise linear regression model did not significantly change the 
outcome, and no other variables besides PCS-12, were significant predictors of medications in 
the first 12-months post-AuBMT.  
Hypothesis Two: Hospitalizations 
The second hypotheses examined whether the aforementioned self-reported psychosocial 
variables would predict number of hospitalizations in the 12 months following AuBMT.  None 
of the bivariate correlations were significant correlates of hospitalization.  A stepwise multiple 
linear regression model was conducted to evaluate whether the five psychosocial predictor 
variables were necessary to predict number of hospitalizations up to twelve months post-
transplant.  None of the variables were significant predictors.  Please see Table 8. Due to the low 
number of hospitalizations per patient (M = 0.55), and low degree of variability (SD = 0.81; see 
Table 2 and Figure B), the outcome of the linear regression was less meaningful.  Therefore, a 
logistic regression model was conducted to more accurately capture the nature of the data.  
Again, no psychosocial predictors were found to significantly predict the variable, 
hospitalization. 
Hypothesis Three: Mortality 
The third hypothesis investigated whether mortality at twelve months post AuBMT 
would be influenced by any of the five self-reported psychosocial variables (DT, Total Problems, 
CES-D score, PCS-12 and/or MCS-12).  None of the bivariate correlations were significant. 
A logistic regression model was conducted to evaluate whether any of the five psychosocial 




None of the variables were found to be significant predictors.  Please see Table 9.  However, 
only 6% of the sample died within 12 months post-transplant.  Therefore, the low 12-month post-
AuBMT mortality rate within this sample size may impact one’s ability to detect a significant 
effect.   
Discussion 
The current study aimed to better understand the impact of pre-AuBMT psychosocial 
factors (i.e., distress, depression and quality of life) on post-AuBMT health outcomes (i.e., 
medication use, hospitalizations, mortality) in hematological cancer patients. The panel of 
psychosocial predictors did not predict hospitalizations or mortality.  However, consistent with 
the study hypotheses, preliminary analyses suggest that psychosocial problems may be 
significant predictors of antiviral, antifungal, antibiotic medication use throughout the 12 months 
following transplant. This research, based on objective chart data, suggests that psychosocial 
factors appear to be meaningfully associated and predictive of medical outcomes including 
antiviral, antifungal, and antibiotic medication use.  Therefore, it may be important to consider 
psychosocial functioning pre-transplant in order to better understand variables impacting 
recovery.  
Medications  
Individuals who self-reported more problems and depressive symptoms were prescribed 
more antiviral, antifungal, and antibiotic medications during the 12 months post-transplant.  
Furthermore, preliminary analyses suggest self-reported physical quality of life may be a 
significant predictor of the number of antiviral, antifungal, and antibiotic medications that a 
patient used during the 12 months after their AuBMT.  Additionally, preliminary analyses 




of collinearity among health outcomes may be important when interpreting these main results.  
For example, although the other two primary variables regarding hospitalizations and mortality 
were not associated with significant differences , the zero order correlations between these 
variables and the primary outcomes  were significant (i.e., those who used more medications also 
had a higher mortality rate and greater number of hospitalizations).  
Main results from the study suggest that certain psychosocial variables may have a 
relationship with post-transplant medication use.  For example, results indicate that the greater 
number of problems and concerns (i.e., family, practical, emotional, spiritual and physical 
problems) and/or depressive symptoms a patient is experiencing prior to AuBMT, the higher 
number of antiviral, antifungal and antibiotic medications may be used post-transplant.  
Additionally, those patients who reported less satisfaction with their physical health quality of 
life, such as worse physical functioning, lower overall general health, and more bodily pain and 
limitations due to physical pain prior to transplant reported that they used more medications post-
AuBMT, even though the medications monitored for this study are not related to the care of pain.  
This last finding was also supported by the stepwise linear regression, in which the physical 
health quality of life score was a significant independent prognostic factor for increased 
medication use following transplant –the worse one views their physical health quality of life 
pre-AuBMT, the more medications that were used post-AuBMT.   
These findings are important in several ways.  First, they address the question of a 
relationship between psychosocial factors and health outcomes, such as infection treatment, 
following AuBMT.   As previously mentioned, antiviral, antifungal and antibiotic medications 
are often used in this population in order to prevent and/or treat infections that may be life-




2015; Bhatti, Almyroudis, Segal, 2006).  Infections are more likely to occur prior to a patient’s 
immune system being fully recovered, during the “engraftment” period (American Cancer 
Society, 2013); therefore, use of these medications may indirectly indicate a poorer immune 
system, which has the potential to lead to slower recovery.  If individuals who view their 
physical health quality of life as poorer pre-AuBMT are taking more medications post-AuBMT, 
this may indicate that they are suffering from a poorer immune system, increased infections, and 
which possible increased risks to their recovery.  
Furthermore, the association between greater depressive symptoms and perceived daily 
problems, which have been shown to be correlated with distress levels (see Table 6; Jacobsen et 
al., 2005), and greater medication use may indicate a relationship between psychosocial 
functioning and health outcomes.  Depression scores for this population fall within a subclinical 
range, based on the CES-D measurement (Radloff, 1977); however, based on the standard 
deviation, scores extend into the clinical range (see Table 2).  Therefore, there is a portion of this 
population suffering from clinical levels of depressive symptoms.  Past research has indicated 
that depression, both subsyndromal and syndromal, directly influences dysregulation of one’s 
immune system, and that depression and stress may lead to prolonged infection or delayed 
wound healing (Kiecolt-Glaser & Glaser, 2002).  Also, other studies have indicated that pre-
transplant distress is related to poorer physical health recovery (Syrjala et al., 2004) and immune 
functioning post-transplant (McGregor et al., 2013). Therefore, increased distress and depression 
may potentially be increasing risk of infection, which in turn is causing individuals to use more 
antiviral, antifungal and antibiotic medications in order to treat such infections.  These results 
further indicate that there may be a relationship between certain psychosocial factors and health 




Hospitalizations and Mortality 
 Psychosocial variables were not found to significantly predict hospitalizations or 
mortality in this study.  It is likely that this data does not possess enough sensitivity due to a low 
hospitalization and mortality rate. Other studies have found that various psychosocial variables 
can impact health outcomes (McGregor et al., 2013; Satin et al, 2009; Pinquart & Duberstein, 
2010; Andorsky et al., 2006).  Had patients been followed for a longer period of time, there may 
have been an increased opportunity to observe significant findings in hospitalization or mortality 
rate.  For example, Prieto and colleagues (2005) followed cancer patients for up to 3 years and 
found that depression predicted higher 1 and 3-year mortality rates in cancer patients after stem-
cell transplantation. Another study, that followed cancer patients for more than a four-year 
period, found that poorer overall pre-BMT adjustment, mood (i.e., greater depressive symptoms) 
predicted shorter life spans (Hoodin et al., 2004).   
Insurance Status 
According to preliminary results, several study variables were found to be significantly 
related to insurance type, including mortality rate, depressive symptoms, and physical and 
mental health quality of life.  Additionally, medications and distress scores were trending toward 
significant association with insurance type.  If the participant sample had been larger, these 
trends may have reached significance.  These associations between insurance status and health 
and psychosocial variables are important when considering the critical role that insurance may 
play in cancer patients’ recovery. 
When looking further into the means for each of the variables significantly related to 
insurance type, it was found that, in general, those in the underinsured group experienced more 




to the group with commercial insurance status, and had higher rates of mortality at 12 months 
post-AuBMT.  The results regarding individuals with Medicare were less conclusive.  However, 
these findings suggest, overall, that insurance status plays a role in health outcomes which is 
consistent with previous studies.  One study, for example, found that, even when controlling for 
various other factors such as self-and physician-rated health status, body mass index, leisure 
exercise, alcohol use, ethnicity/race, and income, a lack of insurance is significantly associated 
with mortality (Wilper et al., 2009).  In addition, there have been multiple studies that have 
shown an effect of insurance payer on cancer care, screening and long-term outcomes 
(Roetzheim, Pal, Gonzalez, Ferrante, Van Durme, Krischer, 2000; Hsia, Kemper, Kiefe, 2000; 
Roetzheim, Pal, Tenant et al., 1999; Ayanian, Kohler, Abe, Epstein, 1993 as cited in Kelz et al., 
2004).   
In fact, uninsured and underinsured cancer patients have been reported to be at a 
heightened risk for receiving overall substandard care, impaired access to quality healthcare, and 
poorer medical treatment (Kelz et al., 2004).  Kelz and colleagues (2004) found that uninsured 
and Medicaid patients with colorectal carcinoma have a greater risk of developing postoperative 
complications and dying than individuals who are privately insured.  Ayanian and colleagues 
(1993) suggest that uninsured and Medicaid breast cancer patients had worse survival rates than 
those patients with private insurance.  The adjusted risk of death in this study was 49% and 40% 
higher for uninsured and Medicaid patients, respectively, than for privately insured patients in 
the 4-7 years post-diagnosis (Ayanian et al., 1993).  A more recent study by Bristow and 
colleagues (2013) found that among all sociodemographic factors evaluated, “not insured payer 




previous studies heighten the importance of further understanding the role of insurance status 
among individuals with hematological malignancies who have had an AuBMT.  
Findings also suggest an additional risk to recovery may be one’s health insurance status.  
Those individuals who were underinsured experienced worse psychosocial functioning prior to 
transplant, such as increased depressive symptoms and decreased physical health quality of life.  
This is highly concerning given the aforementioned significant relationships between medication 
use and physical health quality of life and depressive symptoms (Table 6).  The current findings 
of a relationship between insurance status and psychosocial functioning are consistent with 
previous studies that suggest that people with psychosocial concerns are more likely to be 
uninsured than those without such issues (Rowan, McAlpine & Blewett, 2013).  This fact is 
concerning when research has shown that, when compared with individuals without a cancer 
history, cancer survivors are more likely to use mental health services (Hewitt & Rowland, 
2002).  In a study that examined a nationally representative sample of 95,615 adults in the U.S., 
researchers found that if all cancer survivors with mental health problems who needed but could 
not access mental health services due to cost had received such care, mental health service use 
would have seen a 62% increase (Hewitt & Rowland, 2002).   
This association between mental health and cancer health outcomes and insurance status 
is highly problematic for successful cancer survivorship and the opportunity for patients to thrive 
post-AuBMT.  Future studies should replicate these important results as there were no apriori 
hypotheses regarding insurance status, and sample size may have not been large enough to detect 






Health Care Outcomes and Cost Offset 
If there is indeed a link between these psychosocial factors (depression, perceived 
problems/distress, and perceived physical health quality of life) and increased medication usage, 
there may be need to further investigate how improving mental health prior to transplant, or 
throughout recovery post-AuBMT may not only improve the patient’s finances, but the financial 
state of the health care system as well. 
While the medication costs to patients may vary depending on the patients’ particular 
insurance provider, and the pharmacy in which the medication was issued, it is worthwhile to 
examine some examples of average medication costs for this population.  Some medications 
were less costly, such as the common antiviral medication Acyclovir and the antifungal, Diflucan 
which, for varying strengths of prescriptions of 30 tablets are in the $30.00 - $70.00 range.  
However, one common antibiotic used in this population was Vancomycin.  The “cash cost” of 
this, or the cost without insurance, according to the KU Cancer Center pharmacy representative, 
is approximately $793.00 for 30 of the 125 mg tablets or $1309.00 for 30 of the 250 mg tablets.  
The amount and strength of tablets prescribed varied widely from patient to patient based on 
overall health, immunity, and strength of active or potential infection.  However, it is important 
to note that often, patients are already struggling financially to pay for the AuBMT alone, along 
with doctor and hospital visits, and have potentially had to cease working, pay for extra childcare 
or household care services, and cover co-pays or out-of-pocket costs for procedures, office visits, 
and medications on top of all of their other expenses.  Financial stressors can play a role in 
exacerbating other mental health issues such as distress and depression (Sharp, Carsin, Timmons, 
2013;Price, Choi, & Vinokur, 2002).  Therefore, with the cost of medication usage potentially 




functioning is associated with increase in medication usage, results from this study may suggest 
that there appears to not only be a deleterious relationship between medication usage, 
psychosocial functioning, and health recovery/disease progression but also between mental 
health and health care costs/usage, creating a potentially vicious cycle for patients. 
While results did not directly support the hypotheses that psychosocial factors predicted 
hospitalizations or mortality post-transplant, it is important to note that this may be due to some 
experimental design limitations which will be discussed in the following section.     
Limitations and Future Directions 
Based on current literature searches, this is the first study that has examined the effect of 
psychosocial functioning on health outcomes in the specific population of AuBMT patients.  
While a significant relationship was found between medication use and psychosocial factors, 
there were less supportive data for that relationship with mortality and hospitalizations. These 
results raised a number of other questions which are currently limitations of this research, but 
potential avenues for future research.   
One limitation is that this is a retrospective chart review study.  Therefore, there were 
some limitations as to what information could be collected about patient demographics and 
health outcomes, for example, there was incomplete data regarding patient ethnicity for the 
sample.  There were data to suggest that a patient’s ethnicity may impact certain factors studied, 
such as psychosocial variables and health outcomes during cancer survivorship (Janz, Friese, Li, 
Graff, Hamilton & Hawley, 2014; Advani et al., 2014; White, Pollack, Smith, Thompson, 
Underwood, & Fairley, 2013).  Therefore, future studies would benefit from replicating aspects 
of this study, but collecting ethnicity data and including such information in analyses to control 




Also, because this was a retrospective chart review study, it was difficult at times to 
determine exact medication dosage.  Dosages for inpatient and outpatient use were calculated 
differently.  If a patient was hospitalized as an inpatient for several days, and they received 
multiple IV doses of a certain medication, each IV dose prescribed was considered a separate 
dose.  Yet, for outpatients, one bottle of medication was tallied as one medication dose, 
regardless of number of tablets in the bottle.  This method was instilled to create consistency 
across both types of patients and to control for dose potency as the IV dose for inpatients tended 
to be much stronger than those given in pill/tablet form to outpatients.  Moreover, because this 
was chart review study, it was not possible to control for adherence to outpatient medications.  
Future studies would highly benefit from investigating medication usage more thoroughly by 
controlling and measuring medication dosage more accurately, or possibly separating inpatient 
and outpatient medication use, as well as developing a system to measure adherence for 
medications prescribed on an outpatient basis.  Adherence measures may help address a separate 
question of whether or not low adherence is related to psychosocial factors, or whether 
adherence contributes to increased infections post-transplant. 
Additionally, due to the retrospective nature of the study as well as the broad use of 
antiviral, antifungal, and antibiotic medications, it was difficult to disentangle age-related 
complications and cancer infection-related complications contributing to medication use.  The 
potential confounding variable of age-related complications was also evident when considering 
mortality rate.  Future studies tracking medication use or mortality rate as health outcomes 
within this population would benefit from thorough documentation to better understand the 




Also, while we found that insurance status seems to play a role in one’s overall well-
being pre-transplant and potentially in one’s survival rates post-transplant, it would be important 
for future studies to more closely investigate other mediating variables associated with a lower 
insurance status.  For example, many studies indicate that those who are underinsured or who do 
not have insurance have limited access to preventive services, have less ability to seek timely 
care, and/or are less likely to receive recommended treatment (Halpern et al., 2007; DeVoe, 
Fryer, Phillips, & Green, 2003; Powell-Griner, Bolen, & Bland, 1999).  These other factors may 
be important variables to examine in understanding the importance of insurance status in this 
population. 
Another limitation is that this study only tracked and measured health outcomes of 
patients for 12 months post-transplant.  In order to gain more comprehensive data regarding 
health outcomes it would be helpful to collect and analyze data for a longer post-transplant time 
period, at least up to 24 months post-transplant.  Research shows that even with the most 
favorable hematological malignancy prognoses, net survival tends to decrease over time 
(Monnereau et al., 2013; American Cancer Society, 2015).  It could be particularly helpful to 
better understand the relationship between psychosocial variables and mortality rates over time 
within this specific population.  For example, when cleaning data it became apparent that 
multiple individuals passed away after the 12-month time point, but these data were unable to be 
captured within the current study parameters.  
An additional limitation was the operationalization of the hospitalization variable.   
Hospitalization re-admission rates were lower than expected.  Following chart review, it became 
apparent that tracking hospitalization re-admissions solely based on whether or not patients were 




usage.  For instance, many patients were hospitalized in the E.R., but did not stay overnight, 
therefore, that data were exempt from analyses.  Also, many patients utilized additional 
outpatient services, such as office visits, to address any additional issues or concerns that arose 
following transplant such as neutropenic fevers or other transplant-related symptoms.  There is 
currently a push within the AuBMT population to transition care from an inpatient to outpatient 
basis (Graff et al., 2015; Leger et al., 2006; Meisenberg, Ferran, Hollenbach, Brehm, Jollon, 
Piro, 1998; Gluck et al., 1997).  This may be why only the most severe cases or complications 
appeared to have led to patients being hospitalized overnight.   Also, the overnight 
hospitalizations ranged from a few days to a few weeks, and the exact number of days per 
hospitalization not fully captured or used in the current analyses.  It may be that not analyzing 
overnight hospitalizations, but the rather the number of days hospitalized, would have allowed 
for greater variability and perhaps would have led to more accurate or conclusive results for this 
health outcome variable. 
Another concern that may be addressed in future studies is the high multicollinearity 
found among this study’s psychosocial variables.   For example, the distress thermometer score 
was significantly correlated with each of the four other psychosocial variables, indicating 
potential overlap in content that each scale measures.  While this is consistent with previous 
research data, particularly when looking at distress scales (Vodermaier, Linden, & Siu, 2009), 
this high level of correlation among variables may present a problem when interpreting the 
stepwise linear regression models. This multicollinearity suggests a need for future studies to 
replicate current findings with this particular population, while employing different statistical 
techniques, such as Structural Equation Modeling (SEM) (Muthen & Muthen, 1998).  This 




variable (i.e., psychosocial functioning).  A latent variable can be simply described as an 
underlying cause of multiple observed behaviors or an important construct that is measured 
indirectly through multiple indicators that capture different aspects of the construct (Muthen, 
2002). 
In addition to using SEM analytic techniques, future studies may benefit from utilizing 
mediation techniques.  Some findings from this current study might indicate possible mediating 
factors that could come to light given a larger sample and/or a longer time frame post-transplant.   
While this study found significant results indicating self-reported physical health quality 
of life predicts medication usage, future research may choose to take these findings a step further 
and investigate what psychotherapeutic or other clinical steps or services could be taken to 
improve physical health quality of life prior to transplant in order to potentially decrease 
medication usage and/or infection and reduce health care costs to patients, the health care 
system, and insurance companies. 
Conclusion 
In summation, findings from this sample of patients with hematological malignancies 
who undergo AuBMT suggested that there is a link between psychosocial functioning and health 
care outcomes.  Those patients who self-reported an increase in problems such as Family 
Problems, Practical Problems, Emotional Problems, Spiritual/Religious Concerns, and Physical 
Problems and/or depressive symptoms were prescribed more medications during the 12 months 
after their transplant.  Furthermore, self-reported physical quality of life proved also to be a 
significant predictor of the number of medications that a patient used during the 12 months after 
their AuBMT.  Additionally, insurance status accounted for differences in individuals’ mortality 




Patients completing AuBMT are a high-risk population for suffering from mental health 
concerns due to their marked lifestyle limitations as part of the treatment and recovery process.  
They are forced to be socially isolated during treatment and recovery, in order to prevent further 
complications to their already compromised immune systems.  Additionally, they may undergo 
changes in a variety of settings in a short period of time such as occupational, financial, family, 
social, and leisure.  These changes not only impact these patients’ physically, but also 
emotionally, and they may suffer from a great amount of distress due to these changes.  
Additionally, the  impact of insurance status across all of the psychosocial and health outcomes 
is an important area for further exploration as it could serve as an impediment to overall 
recovery.  There is much literature investigating mental health outcomes and cancer survivorship 
in general cancer populations, but less is known about this relationship in a population of 
individuals with hematological malignancies who have undergone AuBMT.  Due to each cancer 
diagnosis and treatment being unique and varied, it is important to address the specific needs in 
each population. Through continuing to investigate the important questions addressed in this 
study with this particular population, we will be able to further increase and expand our 
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Descriptive and Frequency Characteristics of Demographic Variables 
Variable N % Min-Max Mean Std. Deviation 
Age (years)     -       -     21-80    58.39       11.71 
Male 67 51.5    
Diagnosis      
    MM 86 66.2    
    NHL 32 24.6    
    HL 11 8.5    
    PCL 1 0.8    
Insurance Status      
    Medicare 56 43.1    
    Commercial 49 37.7    
    Underinsured 25 19.2    
Note. MM= Multiple Myeloma; NHL= Non-Hodgkin’s Lymphoma; HL= Hodgkin’s 


































Descriptive and Frequency Characteristics of Outcome Variables 
Variable N % Min-Max Mean Std. Deviation 
DT   0-10 3.19 2.86 
PPL   0-23 6.35 5.26 
CES-D   0-41 10.29 8.48 
PCS-12   13.06-58.31 36.55 11.57 
MCS-12   28-68 52.67 8.90 
Medications   0-69 13.98 11.83 
Hospitalizations   0-4 .55 .81 
Hospitalizations* 52 40    
Mortality Rate 8 6.2    
Note. DT=Distress Thermometer; PPL=Patient Problem List; CES-D= Center for Epidemiologic 
Studies Depression Scale; PCS-12 = Physical Health Composite Scale-12; MCS-12= Mental 
Health Composite Scale-12 


































Means and Standard Error of Variables by Diagnosis Type  
Variable MM NHL HL 
DT  3.22  (.30) 2.72 (.55) 4.55 (.68) 
PPL 6.69 (.57) 4.88 (.81) 8.09 (1.96) 
CES-D 10.58 (.91) 9.41 (1.48) 11.09 (3.00) 
PCS-12 36.09 (1.28) 38.98 (1.97) 32.62 (3.06) 
MCS-12 52.82 (.94) 52.89 (1.71) 50.17 (2.58) 
Medications 14.28 (1.41) 12.16 (1.34) 18.00 (3.55) 
Hospitalizations .50 (.08) .63 (.15) .73 (.33) 
Mortality .02 (.02) .13 (.06) .18 (.12) 







































Means and Standard Error of Variables by Insurance Status  




  2.49 (.35) 3.39 (.39) 4.12 (.64) 
PPL
a 
5.41 (.66) 6.46 (.71) 7.96 (1.20) 
*CES-D
b 
8.16 (.94) 10.88 (1.19) 13.16 (2.01) 
*PCS-12
a 
37.84 (1.74) 37.74 (1.54) 31.38 (1.82) 
*MCS-12
b 




12.08 (1.55) 13.43 (1.31) 18.96 (3.24) 
Hospitalizations
b 
.51 (.11) .48 (.11) .76 (.19) 
*Mortality
b 
.00  .05 (.03) .20 (.08) 
Note. 
+
= variable is approaching significance (p=.05); * = variable has significant difference 
between means (p<.05); 
a
=equal variances, used ANOVA; 
b














































a p= .076   
PCS-12
b p=.058  p=.056 
MCS-12
a  *p<.05  
Mortality
b p=.055   
Note. 
a
=Games-Howell post hoc test; 
b









































 Table 6 
 Bivariate Correlations of Psychosocial Variables, Health Outcomes, and Individual 
Differences               
 DT PPL CES-D PCS-12 MCS-
12 
Meds Hosp. Mor. Gen. 
DT 1         
PPL .655*** 1        
CES-D .612*** .685*** 1       
PCS-12 -.202* -.404*** -.348*** 1      
MCS-
12 
-.705*** -.648*** -.657*** .108 1     
Meds .096 .179* .220* -.293** -.099 1    
Hosp. .065 .009 .072 -.078 .014 .531*** 1   
Mortal- 
ity 
.050 -.060 .048 -.127 .006 .294** .343*** 1  
Gender -.226** -.052 -.112 -.098 .213* .005 -.107 -.072 1 
Age -.084 -.123 .021 .007 .016 -.075 -.108 .107 -.020 
 
































Stepwise Linear Multiple Regression for Medication Use 
Independent Variables Beta (β) Significance 
PCS-12 -.293** .001 
DT .038 .661 
PPL .072 .437 
CES-D .061 .500 
MCS-12 -.068 .427 













































Stepwise Linear Multiple Regression for Hospitalizations 
Independent Variables Beta (β) Significance 
PCS-12 -.246 .013 
DT -.060 .645 
PPL .002 .990 
CES-D .168 .199 
MCS-12 -.003 .984 













































Logistic Regression for Mortality Rate 
Independent Variables Beta (β) S.E. Significance 
PCS-12 -.068 .041 .095 
DT .189 .191 .324 
PPL -.242 .127 .058 
CES-D .038 .060 .526 
MCS-12 -.002 .063 .977 



























































                      Does not meet current study criteria: 
 Allogeneic  bone marrow transplant          117  








           Excluded: 
 Transplant delayed/not occurring                     3 
 Medical information missing                              3 









































Path Diagram for Stepwise Linear Regression Model for Medication Use 
PCS-12 
Medication 
Use 
 
DT 
PPL 
CES-D 
MCS-12 
-.293** 
.038 
.072 
.061 
-.068 
